Info

Ado-trastuzumab emtansine

  • Mechanism: HER2-targeted antibody-drug conjugated to the antimicrotubular maytansinoid agent, mertansine (DM1)
  • Dosing: 3.6 mg/kg every 3 wks, no renal or hepatic adjustments
  • PK/PD: T1/2 ∼4 d
  • AEs: Hepatotoxicity, ↓ LVEF, pancytopenia, GI tox, neuropathy, ↓ K
  • DDI: CYP3A4 substrate